Chinese Medicine: Subsidiary Obtains Registration Approval for Rosuvastatin and Ezetimibe Tablets

The China Medical Announcement states that its fully-owned subsidiary, Tianfang Pharmaceutical, has received the Drug Registration Certificate for Rosuvastatin and Ezetimibe Tablets approved by the National Medical Products Administration. The dosage form is tablet, with each tablet containing 10mg of Rosuvastatin Calcium and 10mg of Ezetimibe, and the production company is Shandong Langno Pharmaceutical Co., Ltd. As of the disclosure date of the announcement, approximately 24.39 million yuan has been invested in the drug. The sales revenue of this drug in the six major markets in China is estimated to be around 1.46 million yuan in 2024 and approximately 23.53 million yuan in the first three quarters of 2025. This approval will help to enrich the product line and accumulate experience, but the sales of the drug may not meet expectations.